Research

Elsevier,

The Lancet Regional Health - Europe, Volume 15, April 2022

An article on dementia risk, in the context of SDGs 3 and 10, focusing specifically on the association between ethnicity, socioeconomic deprivation, and dementia risk.
Cross-sectional and longitudinal soluble TREM2 levels in CSF according to estimated years to symptom onset (EYO) in carriers and non-carriers of pathogenic variants.
Elsevier,

The Lancet Neurology, Volume 21, April 2022

An article on Alzheimer's disease progression, in the context of SDG 3, focusing specifically on the dynamics of soluble TREM2 and its association with amyloid and tau markers, neuroimaging features, and cognition.
Elsevier,

The Lancet Healthy Longevity, Volume 3, April 2022

An article on interventions for people with mild dementia, in the context of SDG 3, focusing specifically on the benefits and cost-effectiveness of the Journeying through Dementia intervention in England.
Elsevier,

Frontiers in Neuroendocrinology, Volume 65, April 2022

In vitro and in vivo studies showed that melatonin therapy is effective against AD. The emerging novel melatonin-based therapies are potential treatment options in AD.
Elsevier,

European Journal of Vascular and Endovascular Surgery, Volume 63, April 2022

This article explores whether operations for carotid artery diseases reduce the risk of dementia.
Elsevier,

Kanski's Synopsis of Clinical Ophthalmology (Fourth edition)
2023, Pages 289-303

This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by providing insight on a group of inherited disorders that have an effect on the RPE-photoreceptor complex and choriocapillaris, causing a range of symptoms and in many cases gradual visual loss.
Elsevier,

Animal Behaviour, Volume 186, April 2022, Pages 151-177

The authors investigate whether applying multiple welfare indicators’ and triangulating them can lead to converged and corroborating evidence of welfare, or whether the indicators' contradict one another.
Elsevier,

Managing Treatment-Resistant Depression
Road to Novel Therapeutics
2022, Pages 205-219

This chapter briefly reviews the history of ketamine, explores proposed mechanisms of action, outlines data pertaining to efficacy and safety, and considers “real-world” usage and the challenges to implementation.
Elsevier,

Managing Treatment-Resistant Depression
Road to Novel Therapeutics
2022, Pages 1-12

This chapter clearly defines “treatment-resistant depression (TRD)” and “difficult-to-treat depression (DTD)" to help clinicians to understand how to treat patients with depression.

Pages